DMARD

(redirected from Disease-modifying antirheumatic drug)
Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Translations

DMARD

abbr disease-modifying antirheumatic drug. V. drug.
Mentioned in ?
References in periodicals archive ?
The company added that the efficacy and safety of Taltz in AS was demonstrated in two randomised, double-blind, placebo-controlled Phase 3 studies that included 657 adult patients with active AS: COAST-V in patients who are biologic disease-modifying antirheumatic drug (bDMARD)-naive and COAST-W in patients who previously had an inadequate response or were intolerant to tumor necrosis factor (TNF) inhibitors.
Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (e.g.
Taltz may be administered alone or in combination with a conventional disease-modifying antirheumatic drug, corticosteroids, non-steroidal anti-inflammatory drugs and/or analgesics.
Researchers randomly assigned 449 adult patients (80.4 percent women) with moderately to severely active RA and inadequate response or intolerance to at least one previous biologic disease-modifying antirheumatic drug (bDMARD) to a once-daily dose of filgotinib 200 mg (148 patients), filgotinib 100 mg (153 patients), or placebo (148 patients).
Methotrexate is the first-line disease-modifying antirheumatic drug used in patients with RA (Annals of the Rheumatic Diseases, September 2017).
Caption: Figure 3: (a) Number of infections in the patients for whom a biological disease-modifying antirheumatic drug (bDMARD) was initiated each year.
(7) demonstrated that the use of steroids doubled the rate of severe bacterial infections when compared with methotrexate therapy, independent of previous disease-modifying antirheumatic drug use (odds ratio = 2.1), and demonstrated a clear dose-response relationship.
They focused on steroid use and disease-modifying antirheumatic drug (DMARD) use in the 16 weeks before delivery.
Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Methotrexate is a disease-modifying antirheumatic drug (DMARD) that prevents joint damage by slowing growth of synovial tissue, which lines the inside of the joints and grows at an abnormal rate in RA patients.
bridge until disease-modifying antirheumatic drug therapy
If approved by the FDA, tofacitinib would be the first new oral disease-modifying antirheumatic drug (or DMARD) for RA in more than 10 years and the first RA treatment in a new class of medicines known as Janus kinase (JAK) inhibitors, says Pfizer.